Discovering The Role of IGHV4-55 in The Immune System (G28393)

Target Name: IGHV4-55

NCBI ID: G28393

IGHV4-55

Other Name(s): immunoglobulin heavy variable 4-55 (pseudogene) | 4-55P | IGHV455 | Immunoglobulin heavy variable 4-55 (pseudogene)

Discovering The Role of IGHV4-55 in The Immune System

IGHV4-55, also known as immunoglobulin heavy variable 4-55 (pseudogene), is a single-chain variable region antibody that is expressed in various tissues and cells of the human body. It is a member of the Ig family of antibodies, which are a group of glycoproteins that play a critical role in the immune system. IGHV4-55 is one of the many subtypes of the IgV region, which consists of four constant genes and one variable gene.

IGHV4-55 is characterized by its unique structure, which consists of a variable region that includes four constant genes (IgVH1, IgVH2, IgVH3, and IgVH4) and one variable gene (IgVJ) that encodes the variable region. The variable region is responsible for the diversity of the antibody, as it allows the immune system to generate a wide variety of antibodies with different effector functions.

IGHV4-55 is expressed in various tissues and cells of the human body, including the spleen, Peyer's patches, and the B cells. It is also expressed in the placenta, which is a vital organ that plays a critical role in the development and maintenance of the immune system.

One of the key functions of IGHV4-55 is its role in the immune response. IGHV4-55 is one of the main antibodies produced by B cells in response to the presence of foreign antigens. When a B cell encounters an antigen that it cannot recognize, it undergoes clonal expansion, followed by somatic hypermutation, which is the process by which the B cell's genetic material is altered in response to the presence of the antigen. This process leads to the production of a diverse range of antibodies, including IGHV4-55.

IGHV4-55 has also been shown to play a key role in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. In rheumatoid arthritis, for example, IGHV4-55 has been shown to contribute to the development of joint inflammation and tissue damage.

In addition to its role in autoimmune diseases, IGHV4-55 has also been shown to be involved in cancer. For example, studies have shown that IGHV4-55 can be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that IGHV4-55 may be a potential biomarker for cancer, and that it may be worth targeting with therapeutic antibodies.

IGHV4-55 is also of interest as a potential drug target. The immune system is a powerful tool that can be used to attack a wide range of diseases and disorders, including cancer. However, the immune system can sometimes work too efficiently, leading to the development of autoimmune diseases and other disorders. By targeting IGHV4-55 with therapeutic antibodies, researchers may be able to reduce the immune system's response and improve treatment outcomes for a variety of diseases.

In conclusion, IGHV4-55 is a unique and important antibody that plays a critical role in the immune system. Its role in the immune response and its expression in various tissues and cells make it an attractive target for therapeutic antibodies. Furthermore, its involvement in autoimmune diseases and cancer suggests that it may also be a valuable biomarker for these conditions. As research continues to advance, the potential of IGHV4-55 as a drug target and biomarker will continue to be explored.

Protein Name: Immunoglobulin Heavy Variable 4-55 (pseudogene)

The "IGHV4-55 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV4-55 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets